Department of Organic Chemistry, University of Vigo, Spain.
Curr Drug Metab. 2010 May;11(4):307-14. doi: 10.2174/138920010791514243.
Efficient drugs such as statins or mevinic acids are inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), an enzyme responsible for the double reduction of 3-hydroxy-3-methyl-glutaryl coenzyme A. These compounds promoted the synthesis and evaluation of new inhibitors for HMGR, named HMGRIs. The high number of possible candidates creates the necessity of Quantitative Structure-Activity Relationship models in order to guide the HMGRI (3-hydroxy-3-methyl-glutaryl coenzyme A inhibitor) synthesis. In this work, we revised different computational studies for a very large and heterogeneous series of HMGRIs. First, we revised QSAR studies with conceptual parameters such as flexibility of rotation, probability of availability, etc; we then used the method of regression analysis; and QSAR studies in order to understand the essential structural requirement for binding with receptor. Next, we reviewed 3D QSAR, CoMFA and CoMSIA with different compounds to find out the structural requirements for 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitory activity.
高效药物,如他汀类药物或莫维尼酸,是胆固醇生物合成限速酶 3-羟-3-甲基戊二酰辅酶 A 还原酶(HMGR)的抑制剂,该酶负责 3-羟-3-甲基戊二酰辅酶 A 的双还原。这些化合物促进了 HMGR 的新抑制剂的合成和评估,称为 HMGRIs。大量可能的候选药物需要定量构效关系模型来指导 HMGRI(3-羟-3-甲基戊二酰辅酶 A 抑制剂)的合成。在这项工作中,我们修订了不同计算研究的非常大且异构的 HMGRIs 系列。首先,我们修订了概念参数(如旋转灵活性、可用性概率等)的 QSAR 研究;然后使用回归分析方法;以及 QSAR 研究,以了解与受体结合的基本结构要求。接下来,我们回顾了 3D-QSAR、CoMFA 和 CoMSIA 与不同化合物的关系,以找出 3-羟-3-甲基戊二酰辅酶 A 还原酶(HMGR)抑制活性的结构要求。